Perspectives and opportunities for nanomedicine in the management of atherosclerosis.
The use of nanotechnology for medical purposes--nanomedicine--has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.
Translational and Molecular Imaging Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, BOX 1234, New York 10029, USA.
Mark E
ME
Lobatto
Valentin
V
Fuster
Zahi A
ZA
Fayad
Willem J M
WJ
Mulder
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000473:pathology; D019468:Disease Management; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D006801:Humans; D050997:Nanomedicine / Q000379:methods / Q000639:trends*; D053758:Nanoparticles / Q000008:administration & dosage*